IGRA-话题@MedSci - 梅斯（MedSci）

#IGRA#

9篇内容 | 1096人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1952142, encodeId=0a39195214272, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, objectTitle=infigratinib国内处方：对肝内胆管癌患者治疗如何？, objectType=article, longId=302059, objectId=1f78302059ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f78302059ab, replyNumber=0, likeNumber=81, createdTime=2022-10-31, rootId=0, userName=sodoo, userId=6cc1239, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f78302059ab, moduleTitle=infigratinib国内处方：对肝内胆管癌患者治疗如何？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1f78302059ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952143, encodeId=478619521434d, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, objectTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, objectType=article, longId=723401, objectId=df51e23401fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df51e23401fa, replyNumber=0, likeNumber=83, createdTime=2022-12-14, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df51e23401fa, moduleTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=df51e23401fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952141, encodeId=9bd91952141f1, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, objectTitle=Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性, objectType=article, longId=215464, objectId=286f215464c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286f215464c0, replyNumber=0, likeNumber=88, createdTime=2022-03-26, rootId=0, userName=sodoo, userId=6cc1239, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286f215464c0, moduleTitle=Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=286f215464c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952140, encodeId=2a0c19521403d, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, objectTitle=Br J Cancer：Migrastatic：转移性黑色素瘤的潜在抗转移治疗药物, objectType=article, longId=213534, objectId=bbe3213534a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbe3213534a2, replyNumber=0, likeNumber=77, createdTime=2022-02-13, rootId=0, userName=sodoo, userId=6cc1239, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbe3213534a2, moduleTitle=Br J Cancer：Migrastatic：转移性黑色素瘤的潜在抗转移治疗药物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bbe3213534a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952139, encodeId=6693195213957, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, objectTitle=Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关 , objectType=article, longId=200106, objectId=c2aa200106d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2aa200106d4, replyNumber=0, likeNumber=0, createdTime=2020-12-15, rootId=0, userName=sodoo, userId=6cc1239, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2aa200106d4, moduleTitle=Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c2aa200106d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952138, encodeId=dc131952138e8, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, objectTitle=BMJ:未经治疗的TST或IGRA阳性人群后续结核病风险研究, objectType=article, longId=189846, objectId=d576189846e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d576189846e1, replyNumber=0, likeNumber=122, createdTime=2020-09-25, rootId=0, userName=sodoo, userId=6cc1239, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d576189846e1, moduleTitle=BMJ:未经治疗的TST或IGRA阳性人群后续结核病风险研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d576189846e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952137, encodeId=6de7195213e7e, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, objectTitle=Actigraphy监测肺纤维化患者具有临床意义, objectType=article, longId=159222, objectId=1ee815922241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ee815922241, replyNumber=0, likeNumber=67, createdTime=2019-12-23, rootId=0, userName=sodoo, userId=6cc1239, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ee815922241, moduleTitle=Actigraphy监测肺纤维化患者具有临床意义, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1ee815922241)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952136, encodeId=fe16195213690, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, objectTitle=2018年欧洲肿瘤内科学会：Infigratinib在胆管癌中的全新结果, objectType=article, longId=151519, objectId=abe5151519ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abe5151519ba, replyNumber=0, likeNumber=71, createdTime=2019-06-19, rootId=0, userName=sodoo, userId=6cc1239, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abe5151519ba, moduleTitle=2018年欧洲肿瘤内科学会：Infigratinib在胆管癌中的全新结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=abe5151519ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952135, encodeId=ded3195213559, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, objectTitle=FDA：Omnigraft可用于治疗糖尿病足, objectType=article, longId=61938, objectId=bdf561938dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdf561938dc, replyNumber=0, likeNumber=82, createdTime=2016-01-14, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdf561938dc, moduleTitle=FDA：Omnigraft可用于治疗糖尿病足, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bdf561938dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IGRA

2020-05-29

sodoo (审核中...)

前往app查看评论内容

#IGRA#

infigratinib国内处方：对肝内胆管癌患者治疗如何？

2022-10-31

zhouqu_8 (审核中...)

前往app查看评论内容

#IGRA#

Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效

2022-12-14

sodoo (审核中...)

前往app查看评论内容

#IGRA#

Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性

2022-03-26

sodoo (审核中...)

前往app查看评论内容

#IGRA#

Br J Cancer：Migrastatic：转移性黑色素瘤的潜在抗转移治疗药物

2022-02-13

sodoo (审核中...)

前往app查看评论内容

#IGRA#

Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关

2020-12-15

sodoo (审核中...)

前往app查看评论内容

#IGRA#

BMJ:未经治疗的TST或IGRA阳性人群后续结核病风险研究

2020-09-25

sodoo (审核中...)

前往app查看评论内容

#IGRA#

Actigraphy监测肺纤维化患者具有临床意义

2019-12-23

sodoo (审核中...)

前往app查看评论内容

#IGRA#

2018年欧洲肿瘤内科学会：Infigratinib在胆管癌中的全新结果

2019-06-19

zhaojie88 (审核中...)

前往app查看评论内容

#IGRA#

FDA：Omnigraft可用于治疗糖尿病足

2016-01-14

科室
- - 订阅+
  - 更多科室
工具
服务